SpeechVive

Executive Summary

SpeechVive is a digital health company focused on addressing speech impairments in individuals with Parkinson's disease through a wearable device that automatically triggers the brain to speak louder and more clearly. Founded in 2011 and headquartered in West Lafayette, Indiana, the company has developed a registered FDA Class I medical device that provides immediate improvement without requiring intensive, long-term speech therapy. The device is already covered by Medicare, the VA, and commercial insurance, indicating strong reimbursement support and market validation. SpeechVive operates in the intersection of digital health and neuroscience, offering a non-invasive solution that enhances quality of life for Parkinson's patients. With a lean operational model and existing commercial traction, the company is well-positioned to scale its reach within the Parkinson's community. However, as a private company with limited public data on funding or valuation, its growth trajectory remains somewhat opaque. The company's device is a proven intervention that bypasses traditional therapy limitations, yet adoption may be constrained by awareness and physician endorsement. Overall, SpeechVive represents a niche but impactful player in the neurodegenerative disease space, with potential for broader insurance coverage and clinical adoption as evidence accumulates.

Upcoming Catalysts (preview)

• Q4 2026Expansion of insurance coverage to additional private payers and international markets70% success
• Q2 2027Publication of new clinical data demonstrating long-term efficacy60% success
• Q3 2027Launch of next-generation device with enhanced features or telehealth integration50% success